Article By:
ChinaBio® Today
Saturday, June 3, 2023 1:00 PM EDT
Hangzhou Betta Pharma acquired greater China rights for a novel non-small cell lung cancer drug from Boston’s C4 Therapeutics in a deal worth up to $392 million. Additionally, Lynk Pharma of Hangzhou raised $28 million in a Series C1 financing.